ClinicalTrials.gg
CompletedNCT02947438BEAT_002Updated Nov 23, 2022

Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

A Phase 3 interventional study of EPREX® and EPIAO® in Renal Anemia, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Completed at 19 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
32nd of 112
207 · median 71
Started
2015
with 1 other
Phase 3
45 of 126
1 open now
Registered
120th of 126
by date

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 32nd largest by enrollment of the 112 interventional ones that give a count, is one of 2 that started in 2015, is one of 45 in phase 3, and was the 120th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 214 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Anemia studies recruiting now, 67 (55%) set no upper age limit and 36 (30%) stop at 75 or younger; 33 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

This study is aimed to comprehensively establish the bio-similarity/bioequivalence in EPIAO® and EPREX® in terms of 52-week comparisons in efficacy, safety and immunogenicity. The targeted population is anaemia patients with end-stage chronic renal disease who previously received epoetin treatment and on haemodialysis.

Read the detailed description

This is a prospective, randomized, double blind, parallel group two arm study to establish the therapeutic equivalence, safety and tolerability of EPIAO® as compared to EPREX® in the treatment of CKD related anaemia in subjects who are on haemodialysis. A total of 264 subjects will be randomized into two groups in a 1:1 ratio. Treatment arm A will receive EPIAO® 1-3 times a week, intravenously for period of 52 weeks and treatment arm B will receive EPREX, 1-3 times a week, intravenously for period of 52 weeks.

03

Conditions studied

  • Renal Anemia

Browse trials for

Keywords

  • Renal anemia
  • Haemodialysis
  • Maintenance phase
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between the age of 18 to 75 years
  • Subjects with end stage renal disease (CKD stage 5) on hemodialysis and on epoetin treatment for at least 3 months prior to screening
  • Subjects with between 10 g/dl to 12 g/dl
  • Subjects who are on clinically stable haemodialysis (defined as no changes of dialysis regimen and/or dialyzer) for at least 3 months prior to screening
  • Subjects willing to provide a written
  • Subjects with serum ferritin ≥ 200 μg/L and/or transferrin saturation ≥ 20%
  • Subjects with a of more than at least study period in clinical judgment of the investigator

Exclusion criteria

Exclusion Criteria:

  • Subjects with anaemia due to other reasons (that is not renal anaemia)
  • Subjects who have undergone blood transfusion within the last 3 months
  • Subjects with major complication such as severe/chronic infections or bleeding or aluminum toxicity
  • Subjects with suspected or known pure red cell aplasia (PRCA)
  • Subjects with a history of aplastic anaemia
  • Subjects with uncontrolled diabetes (fasting blood glucose > 240 mg/dl) or uncontrolled hypertension (systolic blood pressure > 180 mm Hg, diastolic blood pressure > 110 mm Hg)
  • Subjects with known to any of the ingredients of the products, the mammalian cell-derived product or human albumin products
  • Subjects with history of seizure disorder
  • Subjects with hematological disorder
  • Subjects with hyperparathyroidism
  • Subjects with congestive heart failure and/or angina ( class III and IV)
  • Subjects with myocardial infarction or stroke in the preceding 6 months of screening
  • Subjects with active in the previous 5 years
  • Subjects with gastrointestinal bleeding in the past 6 months
  • Subjects with therapy in the previous 3 months
  • Subjects with active virus (HBsAg) (positive for HBsAg and IgM anti-HBc) and virus (HCV) (positive for Anti-HCV antibody) and (HIV)
  • Female subjects who are pregnant, breast-feeding, planning to be pregnant during the study, or women of (any woman who is not surgically sterile i.e. bilateral tubal ligation, total hysterectomy or \< 2 years post menopause) not using a reliable method of double (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period
  • Subjects participating in trials involving erythropoietin in the past 6 months before screening.Subjects currently participating or participation in an investigational study within 30 days prior screening
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Active comparator
    Reference group

    Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease. Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks.

    Drug: EPREX®

  • Experimental
    Experimental group

    Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease. Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks.

    Drug: EPIAO®

Interventions

  • Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease. Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.

    Also known as: Recombinant human erythropoietin

  • Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease. Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.

    Also known as: Recombinant human erythropoietin

06

What researchers measure

Primary outcomes

  1. Mean absolute change in haemoglobin level from baseline to 6 months

    Mean absolute change in haemoglobin level from baseline to 6 months after treatment with EPIAO/EPREX in parallel groups (g/dl).

    Time frame: from baseline to 6 months

  2. Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 6 months

    Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 6 months after treatment with EPIAO/EPREX in parallel groups (IU/kg/week).

    Time frame: from baseline to 6 months

Secondary outcomes

  1. Mean absolute change in haemoglobin level from baseline to 9 months

    Mean absolute change in haemoglobin level from baseline to 9 months after treatment with EPIAO/EPREX in parallel groups (g/dl).

    Time frame: from baseline to 9 months

  2. Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 9 months

    Mean absolute change in weekly epoetin dosage per kg body weight from baseline to 9 months after treatment with EPIAO/EPREX in parallel groups (IU/kg/week).

    Time frame: from baseline to 9 months

  3. Proportion of subjects with hemoglobin values are within 10 - 12 g/dl

    Proportion of subjects with hemoglobin values are within 10 - 12 g/dl for the last 4 weeks of the period for assessment of treatment of efficacy and safety (weeks 32-36)

    Time frame: weeks 32-36

  4. Incidence of blood transfusions

    Incidence of blood transfusions

    Time frame: 52 weak

Other outcomes

  1. Incidence and nature of adverse events

    Incidence and nature of adverse events

    Time frame: 52 weak

  2. Incidence of drug related adverse events

    Incidence of drug related adverse events

    Time frame: 52 weak

  3. Number of subjects who prematurely withdrew from the study due to AE and SAE

    Number of subjects who prematurely withdrew from the study due to AE and SAE

    Time frame: 52 weak

  4. Number of subjects with presence of anti-erythropoietin antibodies (anti-EPO Ab)

    Number of subjects with presence of anti-erythropoietin antibodies (anti-EPO Ab)

    Time frame: 52 weak

07

Study locations

19 sites
  • State Budgetary Healthcare Institution "Volgogradskiy Regional Center of Urology and Nephrology"
    Volzhskiy, Volgogradskaya Region 404120, Russian Federation
  • State budgetary healthcare institution of Moscow region "Moscow Regional Scientific Research and Clinical Institute named after M.F.Vladimirsky", Department of Transplantation, nephrology and surgical hemocorrection
    Moscow, 129110, Russian Federation
  • State Budgetary Healthcare Institution of the Republic of Karelia "V.A. Baranov Republican Hospital"
    Moscow, 185019, Russian Federation
  • State budgetary healthcare institution "City Clinical Hospital № 1" of Orenburg
    Orenburg, 460040, Russian Federation
  • State Budgetary Educational Institution of Higher Professional Education "North-Western State Medical University named after I.I. Mechnikov " Ministry of Health of Russian Federation
    Saint Petersburg, 191015, Russian Federation
  • The Federal State Budgetary Institute "The Nikiforov Russian Center of Emergency and Radiation Medicine" of the Ministry of Russian Federation for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters
    Saint Petersburg, 191015, Russian Federation
  • St- Petersburg state budgetary healthcare institution "City Mariinsky Hospital", department of hemodialysis
    Saint Petersburg, 191104, Russian Federation
  • State budgetary institution "St-Petersburg' scientific-research institution of emergency n.a Dzanelidze)"
    Saint Petersburg, 192242, Russian Federation
  • St-Peterburg State healthcare institution "Municipal hospital of "Elizabethan Hospital
    Saint Petersburg, 195427, Russian Federation
  • Saint-Petersburg State Budgetary Healthcare Institution "City Hospital No. 15"
    Saint Petersburg, 198205, Russian Federation
  • Federal State Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation
    Samara, 443099, Russian Federation
  • Bamrasnaradura Infectious Disease Institute
    Bangkok, 10700, Thailand
  • Bhumibol Adulyadej hospital
    Bangkok, 10700, Thailand
  • BMA hospital
    Bangkok, 10700, Thailand
  • Chulalongkorn King Memorial hospital
    Bangkok, 10700, Thailand
  • Klongton Hospital
    Bangkok, 10700, Thailand
  • Phramongkutklao hospital
    Bangkok, 10700, Thailand
  • Rajavithi hospital
    Bangkok, 10700, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Oct 2021 and a completion of Oct 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Oct 27, 2016
Start
Dec 2015
Primary completionActual
Oct 9, 2021
CompletionActual
Oct 9, 2021
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02947438
Collaborators
Navitas Life Sciences GmbH
Responsible party
Sponsor
First posted
Oct 27, 2016
Start date
Dec 2015
Primary completion
Oct 9, 2021
Completion
Oct 9, 2021
Last update
Nov 23, 2022

Study contacts

Bolong Miao, Doctoral
study director · Shenyang Sunshine Pharmaceutical Co., LTD.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion